Article Text

Download PDFPDF
Quit attempts in response to smoke-free legislation in England
  1. Lucy Hackshaw1,
  2. Andy McEwen2,
  3. Robert West2,
  4. Linda Bauld1
  1. 1UK Centre for Tobacco Control Studies, Department of Social and Policy Sciences, University of Bath, Bath, UK
  2. 2Cancer Research UK Health Behaviour Research Centre, University College London, UK Centre for Tobacco Control Studies, London, UK
  1. Correspondence to Lucy Hackshaw, UK Centre for Tobacco Control Studies, Department of Social and Policy Sciences, University of Bath, Bath BA2 7AY, UK; l.e.hackshaw{at}bath.ac.uk

Footnotes

  • Funding This study was part-funded by Cancer Research UK, who had no involvement in the study design, collection, analysis or interpretation of data, in the writing of the report or the decision to submit the paper for publication. All the authors are members of the UK Centre for Tobacco Control Studies. Funding from the British Heart Foundation, Cancer Research UK, the ESRC, the MRC and the NIHR, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged.

  • Competing interests LH and LB have no competing interests regarding this paper.

    AMc and RW have both received research and travel funding from, and undertaken consultancy for, manufacturers of smoking cessation medications (GlaxoSmithKline Consumer Healthcare, McNeil Healthcare (UK) Limited, Novartis Consumer Health and Pfizer Ltd).

  • Ethical approval Ethical approval was sought and gained from the University College London Graduate School Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding This study was part-funded by Cancer Research UK, who had no involvement in the study design, collection, analysis or interpretation of data, in the writing of the report or the decision to submit the paper for publication. All the authors are members of the UK Centre for Tobacco Control Studies. Funding from the British Heart Foundation, Cancer Research UK, the ESRC, the MRC and the NIHR, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged.

  • Competing interests LH and LB have no competing interests regarding this paper.

    AMc and RW have both received research and travel funding from, and undertaken consultancy for, manufacturers of smoking cessation medications (GlaxoSmithKline Consumer Healthcare, McNeil Healthcare (UK) Limited, Novartis Consumer Health and Pfizer Ltd).

  • Ethical approval Ethical approval was sought and gained from the University College London Graduate School Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.